Abstract Human immunodeficiency virus type I enhancer binding protein 2 (HIVEP2) has been previously associated with intellectual disability and developmental delay in three patients. Here, we describe six patients with developmental delay, intellectual disability, and dysmorphic features with de novo likely gene-damaging variants in HIVEP2 identified by whole-exome sequencing (WES). HIVEP2 encodes a large transcription factor that regulates various neurodevelopmental pathways. Our findings provide further evidence that pathogenic variants in HIVEP2 lead to intellectual disabilities and developmental delay.
Introduction
Human immunodeficiency virus type I enhancer binding protein 2(HIVEP2), also referred to as MIBP1, ZAS2, ZNF40B, MBP-2, and Schnurri-2, is a gene that has been associated with intellectual disability and developmental delay [1, 2] . HIVEP2 encodes a large transcription factor that regulates various neurodevelopmental pathways. To date, three patients with loss-of-function mutations in HIVEP2 have been published, all with developmental delay, intellectual disability, hypotonia, and dysmorphic features [1] . In this paper, we present six additional patients with de novo variants in HIVEP2, identified through whole-exome sequencing (WES), with phenotypes similar to those previously published as well as some additional clinical features. Five of the patients have predicted loss-of-function variants, while the sixth has a missense variant that is predicted to be damaging. Our cases provide further evidence that pathogenic variants in HIVEP2 cause neurodevelopmental disorders.
Methods
This study was approved by the Institutional Review Board of Columbia University. Informed consent was obtained from all individual participants included in the study. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article. Genomic DNA was extracted from whole blood from the affected children and their parents. Exome sequencing for patients 1-4 was performed on exon targets isolated by capture using the Agilent Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA). The sequencing methodology and variant interpretation protocol for patients 1-4 have been previously described [3] . The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (http://www.ncbi.nlm.nih.gov/ clinvar/submitters/26957/).
Whole-exome sequencing for patient 5 was performed using the SureSelect XT Human All Exon V5 kit (Agilent) at a mean target depth of 100×. The target is defined as all coding exons of UCSC and Ensembl ±20-bp intron flanks. Reads for patients 5 and 6 were aligned to Hg19 using BWA (BWA-MEM v0.7.5a), and variants were called using the GATK haplotype caller (v2.7-2). Detected variants were annotated, filtered, and prioritized using the Bench lab NGS v.3.1.2 platform (Cartagenia, Leuven, Belgium). De novo mutation analysis was done by filtering all detected variants against parental and population variants which were confirmed by Sanger sequencing. For patient 6, the laboratory used the SureSelectXT Clinical Research Exome (Agilent) kit.
Results
W E S w a s p e r f o r m e d o n 3 6 9 9 p a t i e n t s w i t h neurodevelopmental disorders within the study time period of patients 1-4. For those four patients, WES produced an average of ∼9 GB of sequence per sample. Mean coverage of captured regions was ∼135× per sample, with >95 % covered with at least 10× coverage, an average of >94 % of base call quality of Q30 or greater, and an overall average mean quality score of >Q36. Filtering of common SNPs, manual curation, evaluation of predicted effects of rare variants and known function of the genes and associated human conditions, and examination of overlapping phenotypes of individuals with de novo variants in the same gene identified variants in HIVEP2 as likely gene damaging in four probands in the series of 3699 patients (0.1 %). Two additional patients with de novo likely gene-damaging variants in HIVEP2 were identified through GeneMatcher [4] .
Six unrelated patients ranging from 2 to 14 years of age were found to have novel, heterozygous de novo variants in HIVEP2: two nonsense, three frameshift, and one missense variant (Fig. 1 ). Maternity and paternity were confirmed as part of quality control in the WES analysis, and all HIVEP2 variants were confirmed by Sanger sequencing in the proband and both parents and were de novo and absent in both parents. None of the variants is present in ExAC [5] and RVIS score for this gene is −2.28 (1.36 %), indicating that the gene is intolerant to variation [6] . The missense variant is a nonconservative amino acid substitution (p.Asp397Tyr) and is located at a conserved position. In silico tools SIFT, Provean, MutationTaster, and CADD all predict it to be pathogenic [7] [8] [9] . It was classified as a likely pathogenic variant using the Richards et al. criteria [10] .
All six patients have developmental delay, intellectual disabilities, and mild dysmorphic features (Fig. 2) . Four of the children have hypotonia, and one has hypertonia. Gross motor milestones were delayed. Two of the children are nonverbal while another has only three words. One child not only can speak in full sentences but also imitates and is difficult to understand, and the 6-year-old child speaks in only three-to four-word sentences. The IQ was not consistently available but ranged from 50 to 75. The clinical course was largely one of severe delays in development but some gains in developmental milestones. Two of the children have seizures. Behavioral issues are common and include autism, hyperactivity, anxiety, and oppositional behaviors. MRI of the brain did not generally demonstrate structural anomalies although there was mild volume loss in patient and another patient had incomplete myelination at 4 years old. Notably, three of the children are microcephalic and another child has a head circumference <10 %. Medical issues are not common, and gastrointestinal issues of constipation and gastroesophageal reflux disease are reported. Ophthalmologic issues were reported in three patients and included strabismus and amblyopia. Five individuals with chromosomal deletions of 6q24.2 ranging in size from 6 to 20 Mb and including HIVEP2 have be en d es cr i b ed [11 ] . A l l fi v e in d i v i d u a l s h a v e neurodevelopmental delay, and some have additional features including short stature and/or craniosynostosis, some features of which may be due to deletion of neighboring genes.
Discussion
We describe six patients with common clinical features of neurodevelopmental disorders including developmental delay/intellectual disabilities and dysmorphic features with heterozygous de novo likely gene-damaging novel variants in HIVEP2, identified through WES. Our series include one de novo missense variant, p.D397Y, which is predicted to be damaging but has not been functionally assessed. The phenotype of patient 4 who carries the p.D397Y variant overlaps with that of the other patients in our series but is nonspecific. Most of the children are nonverbal or minimally verbal. Additional less consistent features in our series include microcephaly without associated brain malformations, seizures, and a range of behavioral problems commonly observed in individuals with intellectual disabilities including autism, attention deficit, oppositional defiance, and anxiety. Our series is consistent with and expands the phenotype previously reported by Srivastava et al. describing three patients with loss-offunction de novo variants in HIVEP2 [1] . Common features across all nine patients include hypotonia, developmental delay, intellectual disability, and dysmorphic features (Table 1) [1] [2] .
HIVEP2 is hypothesized to cause disease through its involvement in the somatostatin receptor pathway, which has been previously associated with intellectual disability [2] . Our six additional patients provide further evidence that loss-of-function mutations in HIVEP2 cause neurodevelopmental disease.
HIVEP2 is located on 6q23-q24 [12] . It is expressed in the brain and encodes a 2446-amino acid protein that is a member of the ZAS protein family, along with HIVEP1 and HIVEP3. ZAS proteins all contain two zinc finger pairs, a serine/ threonine-rich sequence and an acidic region, and encode large transcription factors involved in growth and development [13] . With specificity provided by the zinc fingers, HIVEP2 binds to the DNA sequence 5′-GGGACTTTCC-3′ in enhancer elements of viral and gene promoters.
The predominance of neurodevelopmental features observed in our six patients, along with the three previously published patients, may be explained by HIVEP2's role in brain development. HIVEP2 has been shown to enhance expression of somatostatin receptor type II (SSRT-2) in the brain. HIVEP2 binds with the initiator-binding protein TCF4 to a TC-rich site in the SSRT-2 promoter and activates transcription. SSRT-2 and HIVEP2 are co-expressed in the frontal cortex and hippocampus [14] . HIVEP2 is also known to repress transcription of key developmental genes, including c-myc, a transcription factor that regulates cell growth, differentiation, and apoptosis [15] as well as genes in the NF-κB pathway, which play a role in neuronal development, function, and survival [16, 17] .
Furthermore, mouse models demonstrate the gene's role in neurologic function, primarily in the hippocampus. Hivep2-knockout mice show decreased maturation of neurons and expression of dopamine receptors in the dentate gyrus region of the hippocampus. Phenotypically, Hivep2-knockout mice demonstrate behavioral abnormalities including anxiety, hyperactivity, working memory deficits, reduced pre-pulse inhibition, and impaired sociability, features consistent with those observed in our patients. [1, 18] .
The six patients in our series support the hypothesis that loss-of-function variants in HIVEP2 are a rare cause of neurodevelopmental abnormalities.
